NDIA.AX vs. CURE.AX
NDIA.AX (Global X India Nifty 50 ETF) and CURE.AX (Global X S&P Biotech ETF) are both exchange-traded funds - NDIA.AX is a Global Equities fund tracking the Global X India Nifty 50 Index, while CURE.AX is a Health & Biotech Equities fund tracking the S&P Biotechnology Select Industry Index. Both are passively managed. Over the past 5 years, NDIA.AX returned 3.53%/yr vs 5.62%/yr for CURE.AX. At a 0.17 correlation, their price movements are largely independent.
Performance
NDIA.AX vs. CURE.AX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NDIA.AX achieves a -16.20% return, which is significantly lower than CURE.AX's 22.66% return.
NDIA.AX
- 1D
- -0.32%
- 1M
- -0.09%
- 6M
- -14.59%
- YTD
- -16.20%
- 1Y
- -19.09%
- 3Y*
- -0.52%
- 5Y*
- 3.53%
- 10Y*
- —
CURE.AX
- 1D
- 0.58%
- 1M
- 17.05%
- 6M
- 20.39%
- YTD
- 22.66%
- 1Y
- 65.69%
- 3Y*
- 21.60%
- 5Y*
- 5.62%
- 10Y*
- —
NDIA.AX vs. CURE.AX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
NDIA.AX Global X India Nifty 50 ETF | -16.20% | -3.68% | 13.96% | 15.07% | 2.37% | 24.83% | -0.22% | 0.08% |
CURE.AX Global X S&P Biotech ETF | 22.66% | 25.25% | 8.13% | 10.63% | -22.98% | -17.10% | 38.31% | 7.30% |
Correlation
The correlation between NDIA.AX and CURE.AX is 0.25, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.25 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.17 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.19 |
Correlation (All Time) Calculated using the full available price history since Jun 19, 2019 | 0.17 |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NDIA.AX vs. CURE.AX — Risk / Return Rank
NDIA.AX
CURE.AX
NDIA.AX vs. CURE.AX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Global X India Nifty 50 ETF (NDIA.AX) and Global X S&P Biotech ETF (CURE.AX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NDIA.AX | CURE.AX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -3.83 | ||
| Sortino ratioReturn per unit of downside risk | -5.25 | ||
| Omega ratioGain probability vs. loss probability | 0.81 | 1.43 | -0.62 |
| Calmar ratioReturn relative to maximum drawdown | -0.78 | 5.80 | -6.58 |
| Martin ratioReturn relative to average drawdown | -1.44 | 14.61 | -16.05 |
Loading charts...
Drawdowns
NDIA.AX vs. CURE.AX - Drawdown Comparison
The maximum NDIA.AX drawdown since its inception was -33.23%, smaller than the maximum CURE.AX drawdown of -59.81%. Use the drawdown chart below to compare losses from any high point for NDIA.AX and CURE.AX.
Loading charts...
Drawdown Indicators
| NDIA.AX | CURE.AX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -33.23% | -59.81% | +26.58% |
Max Drawdown (1Y)Largest decline over 1 year | -24.49% | -11.68% | -12.81% |
Max Drawdown (3Y)Largest decline over 3 years | -26.05% | -28.37% | +2.32% |
Max Drawdown (5Y)Largest decline over 5 years | -26.05% | -50.92% | +24.87% |
Current DrawdownCurrent decline from peak | -21.81% | -5.45% | -16.36% |
Average DrawdownAverage peak-to-trough decline | -6.91% | -27.38% | +20.47% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 13.40% | 4.66% | +8.74% |
Volatility
NDIA.AX vs. CURE.AX - Volatility Comparison
The current volatility for Global X India Nifty 50 ETF (NDIA.AX) is 5.23%, while Global X S&P Biotech ETF (CURE.AX) has a volatility of 9.67%. This indicates that NDIA.AX experiences smaller price fluctuations and is considered to be less risky than CURE.AX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NDIA.AX | CURE.AX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 5.23% | 9.67% | -4.44% |
Volatility (6M)Calculated over the trailing 6-month period | 13.91% | 21.01% | -7.10% |
Volatility (1Y)Calculated over the trailing 1-year period | 15.90% | 25.95% | -10.05% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 16.13% | 30.91% | -14.78% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 19.38% | 31.70% | -12.32% |
Dividends
NDIA.AX vs. CURE.AX - Dividend Comparison
NDIA.AX's dividend yield for the trailing twelve months is around 2.14%, while CURE.AX has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
CURE.AX Global X S&P Biotech ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.06% | 11.64% | 9.47% | 2.05% |
NDIA.AX Global X India Nifty 50 ETF | 2.14% | 1.83% | 1.04% | 1.86% | 4.74% | 0.11% | 0.00% | 0.08% |
Frequently Asked Questions
NDIA.AX and CURE.AX have a correlation of 0.25, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NDIA.AX is categorized as Global Equities, while CURE.AX is Health & Biotech Equities. NDIA.AX tracks Global X India Nifty 50 Index, while CURE.AX tracks S&P Biotechnology Select Industry Index.
Find the right allocation for NDIA.AX and CURE.AX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer